Clarence R. Hurt

Clarence R. Hurt has over fifteen years of experience in the pharmaceutical industry. In 2022, they began working as the Vice President of Medicinal Chemistry & Drug Discovery at Tranquis Therapeutics, Inc. Prior to this, they were the Chief Scientific Officer at Link Therapeutics from 2020-2022. From 2017-2020, they were a Chemistry Consultant and Head of Chemistry at IL-2Rx. From 2016-2017, they were the CEO at Q-Bridge Solar Inc. From 2010-2016, they were the Vice President of Chemistry & Drug Discovery at Prosetta Biosciences Inc. From 2008-2010, they were the Director of Chemistry at Prosetta Bioconformatics. From 2005-2008, they were a Principal Scientist and Senior Scientist at ChemoCentryx.

Clarence R. Hurt's educational history includes a Post Doctoral degree from the University of California, Berkeley in Organic Chemistry (1994-1996), a Ph.D. from the University of Michigan in Medicinal Chemistry (1988-1993), and a Bachelor of Science from Haverford College in Chemistry (1982-1986).